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bstract
A dynamic interplay exists between host and tumor, and the ability of the tumor to evade immune recognition often determines the clinical
ourse of the disease. Significant enthusiasm currently exists for a new immunotherapeutic strategy: the use of immunomodulatory monoclonal
ntibodies that directly enhance the function of components of the anti-tumor immune response such as T cells, or block immunologic
heckpoints that would otherwise restrain effective anti-tumor immunity. This strategy is based on the evidence that development of cancer
s facilitated by the dis-regulation and exploitation of otherwise physiological pathways that, under normal circumstances, down-regulate
mmune activation and maintain tolerance to self. Among these pathways an important role is covered by the Programmed death-1 (PD-
)/PD-Ligand (L) 1 axis. An emerging concept in cancer immunology is that inhibitory ligands such as PD-L1 are induced in response to
mmune attack, a mechanism termed “adaptive resistance”. This potential mechanism of immune resistance by tumors suggests that therapy
irected at blocking the interaction between PD-1 and PD-L1 might syn
mmunity. The anti-PD-1 strategy can be effective in several solid tumors
NSCLC), however in this review we summarize the biological role of P
ationale, clinical challenges and opportunities to target the PD-1/PD-L1 a
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xis in melanoma.
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.1.  Immune  evasion  as  hallmark  in  cancer
Cellular transformation and tumor development result
rom an accumulation of mutational and epigenetic changes
hat alter normal cell growth and survival pathways [1]. In
000, Hanahan and Weinberg reported six biological capabil-
ties (hallmarks) acquired during the multistep development
f human tumors: sustaining proliferative signaling, evading
rowth suppressors, resisting cell death, enabling replicative
mmortality, inducing angiogenesis, and activating invasion
nd metastasis [2]. In the last two decades, based on the emer-
ence of new experimental data, two further hallmarks have
een added to this list: reprogramming of energy metabolism
nd evading immune destruction [3].
This Copernican revolution had its foundation on the
wareness that complete knowledge of cancer development
annot be achieved without recognizing the importance of
he tumor microenvironment, a very important part of which
s played by the immune system. A dynamic interplay exists
etween host and tumor, and the ability of the tumor to evade
mmune recognition (immune surveillance) often determines
he clinical course of the disease [4].
The concept of cancer immune surveillance is based on
he hypothesis that the immune system can suppress the
evelopment or progression of spontaneous malignancies [5].
everal data, first from animal models and later from studies
n cancer patients, confirmed this original concept that the
mmune system can recognize and reject tumors, supporting
he hypothesis that immune evasion by cancer cells plays an
mportant role in the development and progression of tumors
6].
Based on this biological background, cancer immunother-
py focuses on the development of agents that can activate the
mmune system to recognize and kill tumor cells. However,
ntil recently, all the efforts to therapeutically modulate the
mmune system were tempered by disappointing results from
linical trials with cancer vaccines and biochemotherapy regi-
ens, as well as by the low response rates and high toxic
ffect associated with these two strategies [7–14]. A third
pproach known as adoptive cell therapy has shown clinical
enefit for some patients although technical aspects and the
omplexity of the procedures have limited more widespread
se [15]. Despite the initial lack of clinical success, extensive
esearch over the past twenty years yielded the identification
f innovative ways to manipulate the immune response to
ancer.
The regulation of the immune system depends on a fine
ontrol system in which a key role is played by cellular recep-
ors that ensure the activation or inhibition of cells involved
n the control of infections and tumors and development of
utoimmunity. Some of these mechanisms are activating and
ictate whether the response arises, while others play the role
f powerful repressors. Antagonist antibodies acting on such
epressors result in enhanced immune responses, a goal that
m
C
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ay also be achieved with agonist antibodies acting on the
ctivating receptors.
More recently, significant enthusiasm arose for a fourth
mmunotherapeutic strategy: the use of immunomodulatory
onoclonal antibodies that directly enhance the function of
omponents of the anti-tumor immune response such as T
ells or block immunologic checkpoints that would other-
ise restrain effective anti-tumor immunity. This strategy
s based on the evidence that development of cancer is
nabled by the dis-regulation and exploitation of otherwise
hysiological pathways that, under normal circumstances,
own-modulate immune activation and maintain tolerance
o self. A series of therapeutic agents are under clini-
al development, and one of them, which is directed at
he CTL-associated antigen 4 (CTLA-4) inhibitory receptor
Ipilimumab, Yervoy®), has been approved for the treatment
f metastatic melanoma. The list of antagonist agents act-
ng on repressors under development includes anti-CTLA-4,
nti-Programmed death-1 (PD-1), anti-PD-Ligand 1 (L1) or
B7-H1), anti-KIR (killer cell Ig-like receptor), and anti-
GF-. Agonist antibodies currently being investigated in
linical trials target CD40, CD137 (4-1BB), CD134 (OX40),
nd glucocorticoid-induced TNF receptor (GITR) (Fig. 1).
mong these pathways an important role is covered by two
mmunologic checkpoints: the CTLA-4 and the PD-1/PD-L1
xis.
An emerging concept in cancer immunology is that
nhibitory ligands such as PD-L1 are induced in response
o immune attack, a mechanism termed adaptive resistance.
his potential mechanism of immune resistance by tumors
uggests that therapy directed at blocking interaction between
D-1 and PD-L1 might synergize with other treatments that
nhance endogenous antitumor immunity.
In this review we summarize the biological role of PD-
/PD-L1 in cancer by focusing our attention on the biological
ational, clinical challenges and opportunities to target the
D-1/PD-L1 axis in melanoma.
. T  cell  recognition  and  immune  checkpoints
Induction of immune response requires T cells to receive
wo sets of signals from antigen-presenting cells: the T cell
eceptor must recognize complexes of MHC with the antigen
n the surface of an antigen-presenting cell (APC). T cells
nd the T cell receptor complex do not respond to antigen in
olution, but even for the specific antigen they only respond to
ntigen-MHC complexes on the cell surface. This interaction
s necessary, but not sufficient, for T cell activation.
T cell activation also requires a co-stimulatory signal
nvolving interaction of CD28 on the T cell with CD80
r CD86 (B7 family genes) on the APC, which pro-
otes T cell clonal expansion and cytokine secretion [16].
D28 activates a signal transduction pathway acting through
hosphatidylinositide 3-kinases (PI3K), lymphocyte-specific
rotein tyrosine kinase (Lck) and adaptor proteins GRB2
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iig. 1. Agonist antibodies (on the left) and antagonist antibodies (on the righ
nd anti-Programmed death-1 (PD-1).
nd GRB2-related adaptor protein (Grb-2/ITK) to provide
ts co-stimulatory signal for T cell activation.
T cell-mediated immunity is regulated by balancing stimu-
atory and inhibitory signals that regulate the response [17].
n the absence of co-stimulatory molecules, the T cells enter
n unresponsive state known as clonal anergy in which the
 cells are incapable of providing antigen-specific immune
esponses [18].
In physiological conditions, immune checkpoints are cru-
ial for maintaining self-tolerance and for protecting tissues
rom the damage of the immune response to pathogenic infec-
ion.
There is evidence that tumors resist immune attack by
nducing tolerance toward tumor-specific T cells and by
xpressing ligands that bind inhibitory receptors such as
mmune checkpoints. Tumors can result in deregulation of
he immune-checkpoint proteins and develop a mechanism
or immune resistance, especially against T cells that are
pecific for tumor antigens [19].
Preliminary clinical data show that antibody blockage of
mmune checkpoints can substantially enhance therapeutic
ntitumor immunity [19,20]. Unlike conventional antibod-
es used for the treatment of tumors, antibodies that block
mmune checkpoints do not bind directly to the tumor cells,
ut target lymphocyte receptors or their ligands, in order to
odulate their antitumor activity.
Several immunologic treatment options, such as the
nduction of an immune response or the administration of
ntibodies, have been investigated in melanoma and have
hown interesting results [21]. CTLA-4 and PD-1 are the two
ost investigated immune checkpoint receptors in melanomand cancer immunotherapy (Table 1) [22]. CTLA-4 is an
nhibitory membrane receptor expressed exclusively on T
ells, where it primarily regulates the amplitude of the early
T
tgonist agents under development acting on repressors include anti-CTLA-4
tages of T cell activation, counteracting the activity of the T
ell co-stimulatory receptor, CD28.
As reported above, the engagement of the T cell antigen
eceptor by itself is not sufficient for full T cells activation; a
econd co-stimulatory signal is required. This co-stimulation
s mediated by engagement of CD28 on the T cell surface by
embers of the B7 family on APC [23].
These co-stimulatory molecules are integral membrane
roteins expressed on several cells with APC function. These
olecules, including B7.1 (CD80) and B7.2 (CD86), bind to
ther ligands on T cells and provide the second signal for
-cells activation. Limited expression of B7 on APCs is a
echanism for maintenance of peripheral T cells tolerance,
nsuring that T cells activation can only be stimulated by
ppropriate cells [24].
Interestingly, tumor cells do not express B7, and this con-
ributes to their poor capacity to induce immune responses
25,26]. After activation, T cells express CTLA-4, a close
omologue to CD28. CTLA-4 binds members of the B7 fam-
ly with a much higher affinity than CD28 [27]. Accordingly,
TLA-4 expression on the surface of T cells decreases the
ctivation of T cells by competing with CD28 for binding with
D80 and CD86. CTLA-4 exerts distinct effects on the two
ajor subsets of CD4+ T cells: down-modulation of helper
 cell activity and enhancement of regulatory T (TReg) cell
mmunosuppressive activity.
The specific signaling pathways by which CTLA-4 blocks
 cell activation are still under investigation, although a
umber of studies suggest that activation of the protein
hosphatases, SHP2 (also known as PTPN11) and PP2A, is
mportant in counteracting kinase signals that are induced by
CR and CD28.
The central role of CTLA-4 for keeping T cell activa-
ion in check is dramatically demonstrated by the lethal
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Table 1
Similarities and differences between CTLA-4 and PD-1.
PD-1 CTLA-4
Biological function Inhibitory receptor Inhibitory receptor
Expression on Activated T cells, activated B cells, activated NK
cells, TILs in different tumor types
T cells at the time of their initial response to antigen
(activated CD8+ effector T cells)
Major role • Limitation of T cells activity in peripheral tissues
following inflammatory responses
• Limitation of autoimmunity
Regulation of the early stage of T cells activation
Ligands • PD-L1 (B7-H1/CD274)
• PD-L2 (B7-CD/CD273)
• CD80 (B7.1)
• CD86 (B7.2)
Mechanism of action • PD-1 binds to the ligand • CTLA-4 interacts with the ligand
↓ ↓
• Recruitment of phosphatase SHP-2 • Binding with PI3K, phosphatases SHP-2 and
PP2A
• Decreased expression of the cell survival protein
Bcl-xL
• Blockade of lipid-raft expression
↓
• PD-1 inhibits kinases (PI3K/AKT) that are
involved in T cells activation
• Blockade of microcluster formation
NK cells, natural kill cells; CTLA-4, cytotoxic T-lymphocyte antigen 4; PD-1, Programmed death-1; PD-L1, Programmed cell death 1 ligand 1; PI3K,
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ystemic immune hyperactivation phenotype of CTLA-4-
nockout mice.
In experimental models, mice rapidly develop lym-
hoproliferative disease with multiorgan lymphocytic
nfiltration and tissue destruction, including particularly
evere myocarditis and pancreatitis, and die at 3–4 weeks
f age [28]. The severe phenotype of mice lacking CTLA-4
mplies a critical role for CTLA-4 in down-regulating T cell
ctivation and maintaining immunologic homeostasis. In the
bsence of CTLA-4, T cells are activated, can spontaneously
roliferate, and may mediate lethal tissue injury.
.  PD-1/PD-L1  expression  and  biological  function
The PD-1 receptor is a 50–55 kDa type I transmembrane
lycoprotein of the Ig superfamily, with an extracellular
omain showing 21–33% sequence identity with CTLA-4,
D28 and the inducible co-stimulatory (ICOS) molecule,
ut distinct function and ligand specificity [29,30]. PD-1
hows an extracellular IgV region, a transmembrane domain,
nd an intracellular tail. The cytoplasmic domain presents
wo tyrosine residues: one represents an immunoreceptor
yrosine-based inhibitory motif (ITIM), and the other an
mmunoreceptor tyrosine-based switch motif (ITSM) that
ay recruit phosphatases, similar to other negative regulators
31,32].
PD-1 expression is mostly detected at the cell surface
membrane) level, where it exerts its function of inhibitory
eceptor, however, PD-1 expression has also been observed
n the cell cytoplasm [33]. It is as yet unclear whether cyto-
lasmic PD-1 exerts biological functions or merely serves as
B
h repository of the protein, allowing an immediate response
s soon as its expression at the membrane is requested.
PD-1 is expressed on CD4−/CD8−  thymocytes in transi-
ion to CD4+/CD8+ stage and on mature T- and B cells upon
ctivation, while it is not detectable on resting T cells. Thus,
n comparison with CTLA-4, PD-1 has a slightly broader
xpression profile, also present on activated myeloid lineage
ells such as monocytes, dendritic cells and NK cells [34,35].
D-1 is quickly up-regulated on T lymphocytes after expo-
ure to cognate antigen and its expression is controlled by
everal cytokines including IFN-, IL-2, IL-7, IL-15, and
L-21 [36]. Upon antigen clearance, PD-1 expression wanes
ccordingly. In normal tissues, PD-1 signaling in T cells regu-
ates immune responses to diminish damage, and counteracts
he development of autoimmunity by promoting tolerance to
elf-antigens.
Most biological functions of PD-1 have been elucidated by
enerating PD-1-deficient mice with gene knockout technol-
gy. PD-1-knockout mice spontaneously develop phenotypes
f lymphoproliferative autoimmune diseases, accompanied
y a marked accumulation of inflammatory cells in affected
rgans, including CD4+ and CD8+ T cell subsets [37].
utoimmune manifestations in PD-1 mice are different from
hose observed in CTLA-4 −/−  mice, which die at 3–4
eeks of age from massive lymphocytic infiltration and tis-
ue destruction in multiple organs [38]. The PD-1 related
utoimmune phenomena are overall milder and less frequent
han those observed following anti-CTLA-4 therapy. Table 1
ummarizes the main differences between CTLA-4 and
D-1.Two ligands for PD-1, designated PD-1 ligand 1 (PD-L1;
7-H1/CD274) and PD-1 ligand 2 (PD-L2; B7-DC/CD273),
ave been identified based on the similarity to other B7
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uperfamilies. PD-L1 and PD-L2 are type I transmembrane
lycoproteins composed of IgC- and IgV-type extracellu-
ar domains that present 40% amino acid identity sequence
34,39–41]. In contrast to the limited expression of PD-
2 on activated macrophages [42], PD-L1 is more broadly
xpressed on immune and non-hematopoietic cells. Specif-
cally, PD-L1 is constitutively expressed on T- and B cells,
acrophages, and dendritic cells, and is upregulated upon
timulation by proinflammatory cytokines including IFN.
Despite the fact that PD-L1 mRNA has been reported in
 wide range of human healthy tissues and cell types (with
igh expression in placenta, heart, lung and liver, low expres-
ion in spleen, lymph nodes and thymus, and no expression
n the central nervous system), constitutive PD-L1 protein
s much less ubiquitous in normal tissues. PD-L1 protein
as also been reported to be expressed on parenchymal cells
uch as pancreatic islet cells, endothelial cells, muscle cells
nd trophoblasts. Discrepancies between mRNA and protein
xpression are most likely attributable to a series of post-
ranscriptional controls that have not yet been completely
larified [43].
PD-L1-deficient mice do not develop spontaneous autoim-
une diseases, mild-to-moderate levels of lymphocyte
ccumulation are evident in the kidneys, liver, and lung, with
 predominant CD3+/CD8+ component exhibiting signifi-
antly decreased apoptosis [44]. Although the mechanism
nderlying selective accumulation of CD8+ T cells in PD-
1−/− mice remains to be clarified, these findings implicate
 role for PD-L1 in the maintenance of T and cell homeostasis
n peripheral organs. Overall, these data support the hypoth-
sis that the expression of this ligand in non-lymphoid tissue
ells can prevent immune-mediated tissue damage [45].
.1.  Functional  implications  of  PD1/PD-L1  interaction
PD-1/PD-L1 interaction inhibits T lymphocyte prolifer-
tion, survival, and effector functions, induces apoptosis of
ntigen-specific T cells, and promotes the differentiation of
D4+ T cells into Foxp3+ regulatory T cells. The mechanism
y which PD-1 exerts the inhibitory effect has been partially
xplained. As soon as PD-L1 interacts with PD-1, there is
 recruitment of Src homology region 2 domain-containing
hosphatase-1 (SHP-1) and SHP-2, which dephosphory-
ate multiple members of the TCR signaling pathway. This
brogates downstream effects of T-cell activation, including
ytokine production, cell-cycle progression, and the expres-
ion of survival proteins. Furthermore, the inhibition of RAS
nd PI3K/AK3 pathways cooperates to inhibit lymphocyte’
unction and survival (Fig. 2).
Considering that (1) PD-L1 is upregulated in hematopoi-
tic and reticuloendothelial cells, in response to proinflam-
atory cytokines such as IFN-, and (2) PD-1 is expressed toarious degrees on activated T cells, it is reasonable to specu-
ate that the co-expression of ligand and receptor in inflamed
issues mitigates against collateral tissue destruction by T
ells at these sites. The PD-1/PD-L1 axis would therefore be
i
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mportant in mitigating the inflammatory response and in turn
otential autoimmune foci resulting from the dysregulation of
he effector phase of the immune response. This mechanism
s important in various physiological and pathological pro-
esses including feto-maternal tolerance, graft-versus-host
isease, and various autoimmune diseases.
Another piece of the puzzle for understanding the central
ole of the PD-1/PD-L1 axis in the immune response derives
rom studies evaluating the developing of T cell exhaustion.
hile PD-1 is expressed on activated lymphocytes during an
cute inflammatory process to limit tissue damage and, as
oon as the exogenous stimulus is cleared, the PD-1 wanes
ccordingly, the persistent antigen exposure may prevent
he down-regulation of PD-1. Since the immune response
lays an important role in staving off cancer, mechanisms
f immunosuppression hinder productive anti-tumor immu-
ity. T cell exhaustion is one such mechanism. PD-1 has been
dentified as a marker of exhausted T cells in chronic disease
tates, including cancer, and blockade of PD-1–PD-L1 inter-
ctions has been shown to partially restore T cell function.
he development of T cell exhaustion translates into a major
mmune resistance and promotes the immune evasion.
.  PD-1/PD-L1  in  malignant  diseases
Via immunohistochemistry, PD-L1 is constitutively
xpressed in many human cancers [46]. The finding that PD-
1 is commonly upregulated on many different tumor types
ncluding melanoma [47], ovarian cancer [48], lung cancer
49], clear cell renal carcinoma [50], urothelial carcinoma
51], squamous cell carcinomas of the head and neck [52,53],
sophageal cancer [54], cervical cancer [55], breast carci-
oma [56], pancreatic cancer [57], gastric cancer [58], Wilms
umor [59] and glioblastoma [60], and that PD-1 is expressed
n TILs, has created an important rationale for mAb blockade
f this pathway for cancer immunotherapy.
In addition to expression on tumor cells, PD-L1 can be
etected on cells located in the tumor microenvironment, and
igh levels of PD-L1 expression have been reported in TILs
nd tumor-associated macrophages [49,61,62]. However, the
ltimate meaning of the PD-L1 expression on tumor cells
nd other cells in the microenvironment remains to be fully
etermined.
PD-L1 expression on cancer cells may be an adaptive
esponse to immune attack and induced by cytokines, or
onstitutive as a result of oncogenic processes, as occurs in
RAFV600  mutated melanoma. The role of oncogenes to
rive immunosuppression has been suggested but not as yet
larified so far.
Interestingly, in melanoma models there is evidence
hat BRAFV600  mutation, along with the STAT3 signal,
s essential for immune evasion by human melanomas.
ecently, Khalili et al. demonstrated that the activation of the
APK signaling pathway in melanoma cells by oncogenic
RAFV600E leads to the production of interleukin 1 (IL-1)/
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Fig. 2. Upon interaction of PD-L1 with PD-1, there is a recruitment of Src homology region 2 domain-containing phosphatase-1 (SHP-1) and SHP-2, which
dephosphorylate multiple members of the TCR signaling pathway. This abrogates downstream effects of T-cell activation, including cytokine production,
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nd survival.
63]. Tumor-associated fibroblasts (TAFs) respond to IL-1
y upregulating an immunomodulatory transcriptional pro-
ram resulting in the production of COX-2, PD-1 ligands, and
hemokines, as well as in the amplification of IL-1 signaling
Fig. 3). Collectively, these factors and signaling circuitries
uppress cytotoxic T lymphocyte functions and ultimately
romote tumor growth. These data highlight the hypothesis
hat both mechanisms (constitutive and induced) may con-
omitantly contribute to the PD-L1 expression on tumor cells
nd in other cells in the microenvironment, potentially fueling
n immune tolerance state.
However, most of the data so far reported in literature are
eterogeneous in terms of PD-L1 expression, variability in
he assays and cell immunolocalization, as well as cut-off val-
es for positive versus negative PD-L1 immunohistochemical
xpression. Furthermore, PD-L1 expression has been inves-
igated in primary tumors and metastatic tissue samples,
ut little conflicting data is available with regard to the
oncordance/discordance of PD-L1 and PD-1 immunohis-
ochemical expression in paired human tissues from primaryelanomas and respective metastases.
Another role in this complicated puzzle is played by PD-
. Similar to exhausted virus antigen-specific T cells, which
o
s
cAS and PI3K/AK3 pathways cooperates to inhibit lymphocytes’ function
ave been reported in chronic viral infections, the majority
f TILs in melanoma express high levels of PD-1 compared
ith T cells from normal tissues and peripheral blood.
Previous studies on several human cancer types ele-
antly showed that overexpression of PD-L1 in tumor cells
ay allow immune evasion [46]. When PD-L1 binds with
D-1 receptor on T-cells, T-cell function is compromised
hrough induction of apoptosis, suppression of prolifera-
ion, and inhibition of T -cell cytokines release, such as
FN-, IL-4 and IL-2. Furthermore, the PD-1/PD-L1 inter-
ction inhibits T lymphocyte proliferation, survival and
ytokines secretion, promotes the differentiation of CD4-
ositive/CD25-negative/Foxp3-negative T cells into Foxp3+
egulatory T cells (Treg), and induces apoptosis of tumor-
pecific T cells. Treg cells allow tumor cells to grow locally,
nd PD1/PD-L1 pathway on tumor cells causes immunosup-
ression by PD-L1-induced Treg cells.
One study showed that the majority of CD8+ TILs
pecific for the melanoma antigen MART-1 expresses
ignificant levels of PD-1 compared with lower expression
n MART-specific T cells from the peripheral blood of the
ame patients [64]. PD-1 expression by TILs in melanoma
orrelated with an exhausted T cell phenotype and impaired
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Fig. 3. The activation of the MAPK signaling pathway in melanoma cells by oncogenic BRAFV600E leads to the production of interleukin 1 (IL-1)/. Tumor-
associated fibroblasts (TAFs) respond to IL-1 by upregulating an immunomodulatory transcriptional program resulting in the production of COX-2, PD-1
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sigands and chemokines as well as in the amplification of IL-1 signaling. Co
CTL) functions and ultimately promote tumor growth.
ffector function. These data underscore once again that the
ssessment of circulating lymphocytes does not necessarily
eflect what happens in the tumor microenvironment, at the
iological interface between immune system and cancer.
herefore, the evaluation of the immunological profile in
he circulation may be misleading in the assessment of the
nteraction between lymphocytes, APC, other cells in the
icroenvironment, and tumor cells.
In conclusion, all the above reported data suggest that
he constitutively or the cytokine-induced PD-L1 expres-
ion would provide a selection advantage of cancer cells by
nhibiting tumor-specific recognition and elimination by T
ells. PD-L1/PD-1 axis is a potential point of contact between
arget molecules (BRAFV600), immune evasion and tumor
rowth. Therefore, therapeutic antibodies that block PD-1 in
rder prevent the inhibitory interaction between PD-1 and
D-L1 may partially circuit the cancer immune evasion and
licit the immune system to recognize and kill tumor cells.
.  Prognostic  role  of  PD-L1  and  PD-1  in  malignanciesTables 2 and 3 summarize studies on the prognostic
ole of PD-L1 and PD-1 in different tumor types. Overall,
he results published so far are heterogeneous in terms
n
s
Bly, these factors and signaling circuitries suppress cytotoxic T lymphocyte
f patient’ selection criteria and methodology used for
mmunohistochemical analysis. Specifically, difficulties in
omparing results arise from the following considerations:
i) available data are retrospective; (ii) patients with different
umor stages have been included; (iii) primary or metastatic
ites have been included; (iv) different tumor histotypes
ave been compared within the same studies; (v) different
ypes of tissues have been evaluated (frozen versus paraffin-
mbedded samples); (vi) monoclonal and/or polyclonal
ntibodies have been used; (vii) both cytoplasmic and/or
embranous immunostaining have been evaluated to define
ositivity; and finally (viii) different scores of PD-L1 and/or
D-1 positivity have been reported. Thus, the prognostic
ole of PD-L1 and PD-1 in the context of different tumor
ypes requires further investigation and only future studies
ill establish whether PD-L1 is an immune correlate and
redictive marker for response to anti PD-1 antibody.
According to the aim of the present review we will focus
n melanoma. At the time of the present manuscript, three
tudies reported the role of PD-L1 in melanoma patients.
Hino et al. evaluated the intensity of PD-L1 expres-
ion in melanoma specimens (59 primary tumors, 16 lymph
odes, and 4 in-transit metastases). By multivariate analy-
is, immunohistochemical PD-L1 expression correlated with
reslow thickness, disease free, and overall survival [47].
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Table 2
PD-L1 expression and prognosis in malignancies.
Author Na Tumor Tissues/Detection Method Immunostaining Antibody Prognostic role
Thompson [79] 306 Renal cell carcinoma FFPE tissues/IHC Cell-surface membrane
(≥5% tumor staining = PD-L1
positivity)
Anti-PD-L1
MoAb
(5H1)
Yes:
Association
PD-L1 positivity tumor/
- Death
(RR, 3.92; P < 0.001)
- Overall mortality
(RR, 2.37; P < 0.001)
PD-L1 independent prognostic factor
of cancer-specific death
Thompson [50] 429 Renal cell carcinoma Fresh-Frozen tissues/IHC Cell-surface membrane
(≥10% tumor staining = PD-L1
positivity)
Anti-PD-L1
MoAb
(5H1)
Yes:
Association
PD-L1 positivity tumor/
death
(RR, 4.53; P < 0.001)
PD-L1 independent prognostic factor
of cancer-specific death
Taube [66] 150 Melanoma FFPE tissues/IHC Cell-surface membrane PD-L1
expression
(≥5% tumor staining = PD-L1
positivity)
Anti-PD-L1
MoAb
(5H1)
Anti-PD-L1 polyclonal Ab
(4059)
Yes:
Association
PD-L1 positivity tumor/
OS
(P = 0.032)
Gadiot [65] 63 Melanoma FFPE tissues/IHC N/A
(≥1% tumor staining = PD-L1
positivity)
Several Anti-PD-L1
MoAbs
Anti-PD-L1 polyclonal Ab
(4059)
No
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Table 2 (Continued)
Author Na Tumor Tissues/Detection Method Immunostaining Antibody Prognostic role
Hino [47] 59 Melanoma FFPE tissues/IHC Cytoplasm area Anti-PD-L1
MoAb
(27A2)
Yes:
Association
PD-L1 positivity tumor/
- OS
(P = 0.0402)
- PFS
(P = 0.0522)
PD-L1 independent prognostic factor
of OS and PFS
Ohigashi [54] 41 Esophageal cancer Frozen tissues/IHC;
mRNA analysis (Real-time
quantitative PCR)
Cell-surface membrane
or
Cytoplasm area
(≥10% tumor staining = PD-L1
positivity)
Anti-PD-L1
MoAb
(MIH1)
Anti-PD-L2
MoAb
(MIH18)
Yes:
Association
- PD-L1 mRNA expression
positivity/
OS
(P = 0.025)
- PD-L2 mRNA expression
positivity/
OS
(P = 0.003)
- PD-L1 positivity and PD-L2
positivity status/
OS
(P = 0.0008)
PD-L1 and PD-L2 = independent
Prognostic factors of OS
Wu [58] 102 Gastric cancer FFPE tissues/IHC Cytoplasm area
(some nuclear membrane
localization)
Anti PD-L1
MoAb
(2H11)
Yes:
Association
PD-L1 positivity tumor/
OS (P < 0.01)
PD-L1=
independent prognostic factor of OS
(RR = 2.803; P = 0.040)
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Konishi [49] 52 Non-small cell lung
carcinoma
Frozen tissues/IHC Cell-surface membrane
and/or
Cytoplasm area
(focal or scattered pattern)
Anti-PD-L1
MoAb
(MIH1)
Anti-PD-L2
MoAb
(MIH14)
No
Mu [80] 109 Non-small cell lung
carcinoma
FFPE tissues/IHC Cell-surface membrane
and/or
Cytoplasm area
(focal or scattered pattern)
Anti-PD-L1
(clone not specified)
Yes:
Association
PD-L1 positivity tumor/
3 years OS (P = 0.034)
Gao [81] 240 Hepatocellular
carcinoma
FFPE tissues/IHC Cell-surface membrane
and/or
Cytoplasm area
(focal or scattered pattern)
Anti-PD-L1
MoAb
Anti-PD-L2
MoAb
Yes:
Association
PD-L1 positivity tumor/
- DFS
(P = 0.047)
- OS
(P = 0.029)
PD-L1 independent prognostic factor
of DFS
(P = 0.015)
Cariani [82] 42 Hepatocellular
carcinoma
Frozen tissues/mRNA
analysis (Real Time
quantitative PCR)
FFPE tissues/IHC (on 15
HCC samples)
Cytoplasm area Anti-PD-L1 polyclonal Ab Yes:
Association
PD-L1 mRNA expression positivity/
OS
(P < 0.05)
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Table 2 (Continued)
Author Na Tumor Tissues/Detection Method Immunostaining Antibody Prognostic role
Zeng [83] 109 HBV-related
Hepatocellular
carcinoma
FFPE tissues/IHC NA
(≥50% tumor staining = PD-L1
positivity)
Anti-PD-L1
MoAb
Yes:
Association
PD-L1 positivity tumor/
- TFS
(P ≤ 0.001)
- OS
(P ≤ 0.001)
PD-L1 independent prognostic factor
of TFS (P ≤ 0.001) and OS
(P = 0.007)
Karim [55] 115 Cervical cancer FFPE tissues/IHC Cell-surface membrane
(PD-L1/PD-L2)
Anti-PD-L1
MoAb
(5H1)
Anti-PD-L2
MoAb
Anti-PD1
MoAb
No
Nomi [57] 51 Pancreatic cancer Frozen tissues/IHC
mRNA analysis (Real-time
quantitative PCR)
Cell-surface membrane and
Cytoplasm area
(≥10% tumor staining = PD-L1
positivity)
Anti-PD-L1
MoAb
(MIH1)
Anti-PD-L2
MoAb
(MIH18)
Yes:
Association
PD-L1 positivity tumor/
OS
(P  = 0.016)
PD-L1 independent prognostic factor
of OS
(P = 0.022)
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Nakanishi [51] 65 Urothelial cancer Frozen tissues/IHC Cell-surface membrane and/or
Cytoplasm area
(focal pattern)
Anti-PD-L1
MoAb
(MIH1)
Yes:
Association:
PD-L1 positivity tumor/
- OS
(P = 0.021)
- Post-resection recurrence
(P = 0.026)
Cho [62] 45 Oral squamous cell
carcinoma
FFPE tissues/IHC Cell-surface membrane and/or
Cytoplasm area
Anti-PD-L1 polyclonal Ab
(ab82059)
No
Hsu [84] 74 Nasopharyngeal
carcinoma
FFPE tissues/IHC
(46 samples)
Snap-frozen tissue
(28 samples)
NA Anti-human PD-1 polyclonal Ab
Anti-PD-L1
MoAb
(MIH1)
Anti-PD-L2
MoAb
(MIH18)
No
Droeser [85] 1420 Colorectal cancer FFPE tissues-
TMA/IHC
NA
(Score 2–3 tumor staining = PD-L1
positivity;
Intensity of PDL1
Staining=
Score 0: negative
Score 1: very weak expression
Score 2: moderate expression but
weaker than placenta)
Score 3: equivalent to or stronger
expression than placenta)
Anti-PD-L1
MoAb
(27A2)
Anti-PD-L1
Polyclonal Ab
(ab82059)
Yes:
Association
PD-L1 positivity tumor (MoAb)/
OS
(P = 0.0001)
PD-L1 positivity tumor (polyclonal
Ab)/
OS
(P = 0.008)
PD-L1 trend for independent
prognostic factor (P = 0.052)
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Table 2 (Continued)
Author Na Tumor Tissues/Detection Method Immunostaining Antibody Prognostic role
Hamanishi [48] 70 Ovarian cancer FFPE tissues/IHC NA
(Score 2–3 tumor staining = PD-L1/
PD-L2 positivity;
Intensity of PD-L1 and PDL2
staining = -Score 0: negative
-Score 1: very weak expression
-Score 2: moderate expression but
weaker than placenta (PD-L1) and
tonsil (PD-L2)
-Score 3: equivalent to or stronger
expression than placenta or tonsil)
Anti-PD-L1
MoAb
(27A2)
Yes:
PD-L1 independent prognostic factor
of:
- OS (RR, 4.26; 95% CI, 1.39–12.94;
P = 0.011)
- PFS (RR, 2.57; 95% CI, 1.11–5.93;
P = 0.027)
Topalian [67] 42 18
Melanoma
10
Non-small cell lung
carcinoma
7
Colorectal cancer
5
Renal cell carcinoma
2
Prostate cancer
FFPE tissues/IHC NA
(≥5% tumor
staining = PD-L1 positivity)
Anti-PD-L1
MoAb
(5H1)
Yes:
Association
Pretreatment PD-L1 positivity tumor/
Objective Response after treatment
with anti-PD-1 antibody
IHC, immunohistochemistry; FFPE, formalin-fixed and paraffin-embedded; OS, overall survival; DFS, disease free survival; PFS, progression free survival; RR, risk ratio; Ab, antibody; MoAb, monoclonal
antibody; TMA, tissue microarray; TFS, treatment free survival; NA, not applicable; PCR, polymerase chain reaction.
a Number.
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Table 3
PD-1 and prognosis in malignancies.
Author N◦ Tumor Tissues/detection
method
Cell
immunolocalization/cut-
off for
positivity
Antibody Prognostic role
Hsu [84] 74 Nasopharyngeal
carcinoma
FFPE tissues/IHC (46
samples)
Snap-frozen tissue (28
samples)
NA Goat polyclonal antibody anti-human
PD-1 (R&D Systems, Minneapolis)
YES →
Correlation:
PD-1 + -CD8 expression/OS (P = 0.05).
PD-1 + -CD8 expression/DFS (P = 0.007).
PD-1 + CD8 expression/locoregional
recurrence free Survival (P = 0.004).
PD-1 + -CD8
expression/locoregional recurrence-free
survival (four groups) (P = 0.004).
High PD-1 + -CD8 group had a 6.5 times
higher risk of locoregional recurrence
(P = 0.005), a 6.5 times higher risk of
treatment
failure (P = 0.013), and a 9.5 times higher
risk of death (P = 0.015);
PD-1 expression
in intratumoral CD8 cells: independent
effect on the post-treatment outcome
----------------
NO →
No Correlation:
PD1 + -CD8 expression/distant
metastasis-free survival (P = 0.31).
PD-1 + -CD4 expression/
OS (P = 0.56).
PD-1 + -CD4 expression/
DFS (P = 0.90)
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Author N◦ Tumor Tissues/detection
method
Cell
immunolocalization/cut-
off for
positivity
Antibody Prognostic role
Wahlin [86] 70 Follicular lymphoma FFPE tissues/IHC
Tissue microarray
(TMA)
Non-nuclear
Quantification: cell
count = PD-1 positive
cells/sum of total
cellular area
Compartment:
total/follicular/interfollicular
Anti-PD-1 Ab non-specified YES →
Correlation
Follicular PD1 positivity/
favorable prognosis (RR = 0.34, P = 0.01)
along with interfollicular CD8+ cells
(RR = 0.86, P = 0.014) independent of FLIPI
Takahashi [87] 82 (patients treated by
standard R-CHOP as
initial therapy)
Follicular lymphoma NA NA
PD-1 positivity
staining: > 14.4%
Anti-PD1
MoAb
(Abcam 52587)
NO →
No correlation
CR rate/PD-1 positivity patients
No correlation PD-1 positive cells
(≥7.5%)/PFS (P = 0.20)
No correlation PD-1 positive cells
(≥7.5%)/OS (P = 0.60)
PD-1 is not a Independent prognostic factor
Among male patients (n = 43): correlation
PD-1 positive cells/worse PFS (P = 0.03)
Richendollar [88] 91 Follicular lymphoma Tissue microarray
(TMA)/IHC
NA
PD-1 positivity:
>35.6 PD-1 positivity
cells/HPF
Anti-PD1
Polyclonal (Abcam)
YES
Association
PD1 positivity T cells/decreased OSl
(HR = 1.64, P = 0.10)
PD1: independent prognostic factor for
decreased OS
Muenst [89] 189 Hodgkin lymphoma Tissue microarray
(TMA)/IHC
NA
PD-1 positivity:
>23 PD-1 positivity
cells/mm2
Anti-PD-1 Goat antihuman MoAb
(AF1086 R&D Systems)
YES →
PD1 positivity T cells/worse OS
(P = 0.005)
NO →
PD1 is not a Independent prognostic factor
(P = 0.022)
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Shi [90] 56 Hepatocellular
carcinoma
FFPE tissues/IHC,
FACS
Both
cell-surface
membrane and
cytoplasm area
Anti-PD1
Mouse antihuman MoAb (R&D
Systems)
Anti-PD-L1
Mouse antihuman MoAb
(Biolegend), FACS with
PE-conjugated PD-1 and PD-L1
(eBiosciences)
YES →
Correlation
High levels of intratumoral PD1 + CD8+ T
cells/
shorter DFS
(P < 0.001)
Zeng [83] 109 (cryoablation)
23 (IHC)
HBV-related
Hepatocellular
carcinoma
FFPE tissues/IHC NA NA YES
Correlation
PD-1/TFS (P ≤ 0.001)
PD-1/OS (P = 0.001)
Circulating PD-1 expression = independent
poor prognostic factor for TFS (P = 0.046)
N◦, number of patients; FLIP, Follicular Lymphoma International Prognostic Index; R-CHOP, treatment with Rituximab, Cyclophasfamide, Doxorubicin, Vincristine and Prednisolone; FFPE, formalin-fixed
and paraffin-embedded; CR-rate, complete response rate; OS, overall survival; PFS, progression free survival; TFS, treatment free survival; FACS, flow cytometry analysis; RR, risk ratio; MoAb, monoclonal
antibody.
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Gadiot and colleagues evaluated paraffin-embedded tis-
ues of 63 patients with stages III-IV melanoma diagnosed by
he Netherlands Cancer Institute between 2000 and 2004. PD-
1 was analyzed in benign nevi (n  = 10), primary melanomas
n = 43), satellite metastases (n  = 8), in transit-metastases
n = 21), and distant organ metastases (n  = 22). Interestingly,
he authors showed that 20% of the benign nevi samples were
D-L1-positive, while only 5% of primary melanomas were
D-L1 positive. Satellite metastases, in-transit metastases,
ymph nodes and distant metastases were PD-L1 positive in
5%, 40%, 14%, and 18% of cases, respectively. PD-L1 was
ore expressed in satellite and in-transit metastases com-
ared with lymph node, and distant metastases. In this study,
D-L1 did not correlate with disease free or overall survival
65].
Finally, Taube et al. demonstrated a correlation between
D-L1 and the presence of TILs in both nevi and malignant
elanoma: 98% of PD-L1 positive melanomas were associ-
ted with TILs compared with only 28% of PD-L1 negative
elanomas. Furthermore, PD-L1 positive melanocytes were
lmost always localized adjacent to TILs. Interestingly, a pos-
tive correlation between surface PD-L1 expression by tumor
ells (≥5%) and overall survival in metastatic disease in 56
atients was reported. On the other hand, there was no signif-
cant difference in survival in relation to PD-L1 expression
n primary melanoma [66].
There are important differences in the first two above
eferenced studies [47,65]. PD-L1 was evaluated with differ-
nt immunostaining protocols. In Hino’s study, it is unclear
hether the authors tested their antibodies against isotype
ontrols and PD-L1Fc protein blockade to ensure lack of
ackground or unspecific signals.
Another likely explanation for the conflicting results could
e that small series of fewer than 100 melanoma patients
rom diverse origin were analyzed. The most noticeable
ifference between the Asian melanoma patient population
47] and the cohort population evaluated by Gadiot is the
umor type. In the latter, superficial spreading and nodu-
ar melanomas were predominantly diagnosed, whereas in
he cohort of Hino et al., mainly patients with acral lentigi-
ous melanomas were included. The latter have been shown
o preferentially express c-kit amplifications or mutations,
hereas the melanomas from the European cohort are more
ikely to express BRAF mutations. Finally, more women
ere included in Hino’s study. Women are known to have
 better prognosis in melanoma and may have influenced the
rognostic analysis of PD-L1.
Finally, Taube et al. suggest that patients with both PD-
1 expression and TILs in melanoma may have improved
rognosis compared with the group with PD-L1 expression
ithout TILs [66]. This study seems to suggest that the eval-
ation of PD-L1 expression is important but not sufficient to
nderstand the intricate interplay between melanoma and the
mmune system. PD-L1 overexpression in melanoma with
ILS could be suggestive of an active and efficient immune
esponse, and therefore may correlate with a better prognosis.
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.  Clinical  trials  and  future  developments
We performed an extensive “Medline” and Cancerlit
iterature review (1995–2013). Various combinations of
earch terms were used depending on the requirements of
he database being searched. These terms included “PD-
” or “PD-L1” or “B7-H1”, in combination with “cancer
atients” or “melanoma” or “tumor” or “tumour” or “activ-
ty” or “safety” or “phase 1” or “immunotherapy” or
immune checkpoints” or “lymphocytes” or “randomized” or
prospective” or “clinical” or “early phase” or “nivolumab”
r “lambrolizumab”. In addition, relevant references in
ach article were scanned, and we did manual searches of
bstracts from the annual meetings of the American Society
f Hematology (1993–2012), American Society for Clinical
ncology (1993–2013), European Haematology Association
1993–2012), and European Society for Medical Oncology
1998–2013).
Table 4 summarizes the main prospective phase 1
tudies evaluating anti PD-1/PD-L1 antibodies in cancer
atients. Topalian and coll. enrolled 296 patients with
dvanced melanoma, non-small-cell lung cancer, castration-
esistant prostate cancer, or renal-cell or colorectal cancer
o receive BMS-936558 (anti-PD-1 antibody) at a dose
f 0.1–10.0 mg/kg of body weight every 2 weeks for 8
eek-treatment cycles for 12 cycles until progression or
omplete response [67]. Common treatment-related adverse
vents included fatigue, rash, diarrhea, pruritus, decreased
ppetite, and nausea. Grade 3 or 4 drug-related toxicities
ccurred in 14% of patients; moreover, there were three
eaths from pulmonary toxicity. Drug-related serious adverse
vents occurred in 32 of 296 patients (11%). The spec-
rum, frequency, and severity of treatment related adverse
vents were generally similar across the dose levels tested.
rug-related adverse events of special interest (e.g., those
ith potential immune-related causes) included pneumoni-
is, vitiligo, colitis, hepatitis, hypophysitis, and thyroiditis.
n this trial, objective responses were observed in 28% of
elanoma patients. Interestingly, partial sustained, long term
esponses were observed at each cohort level (0.3–10 mg/kg).
t a dose of 3.0 mg/kg, objective responses were noted in
 of 17 patients (41%). As measured by standard RECIST
riteria, objective responses were long lasting, with response
urations of 1 year or more in 13 out of 26 patients who had
 response with 1 year or more of follow-up.
In the same study immunohistochemical analysis was per-
ormed on pretreatment tumor specimens obtained from 42
atients. Objective response was reported in a subgroup of
atients (9/25 patients: 36%) with PD-L1-positive tumors.
hese preliminary data would suggest a relationship between
D-L1 expression on tumor cells and objective response.
Hodi et al. reported the activity and safety of BMS-936558
n patients with previously treated advanced melanoma [68].
MS-936558 was administered every two weeks at doses of
.1–10 mg/kg during dose-escalation and/or cohort expan-
ion. Patients received up to 12 cycles (4 doses/cycle) of
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Table 4
Main prospective phase 1 studies evaluating anti PD-1/PD-L1 antibodies in cancer patients.
Author Tumors Drug Dose/schedule (i.v.) Pts (n) OR (%) PFS OS
Anti PD-1 antibody
Topalian [67] Melanoma
NSCLC
CRPC
RCC
CRC
BMS936558 0.1 mg/kg
0.3 mg/kg
1.0 mg/kg
3 mg/kg
10 mg/kg
Every 2 weeks
296 –
6%
32%
18%
At 24 weeks
47%
67%
56%
NR
Brahmer [91] Melanoma
NSCLC
CRPC
RCC
CRC
MDX1106 0.3 mg/kg
1.0 mg/kg
3 mg/kg
10 mg/kg
39 0
0
17%
10%
NR
Berger [92] Advanced
Hematologic
malignancies
CT-011 0.2 mg/kg
0.6 mg/kg
1.5 mg/kg
3 mg/kg
6 mg/kg
17*
6%
NR At 21 days
76%
McDermott [93] RCC BMS936558
1.0 mg/kg
10 mg/kg
Every 2 weeks
34
28%
31%
At 24 weeks
50%
67%
NR
Patnaik [94] Melanoma
NSCLC
RC
Sarcoma
Carcinoid
MK3475
1.0 mg/kg
3 mg/kg
10 mg/kg
Every 2 weeks
9
NR NR NR
Kudchadkar [95] Melanoma BMS936558
Plus vaccines#
1.0 mg/kg
3 mg/kg
10 mg/kg
Every 2 weeks
30
NR NR NR
Hodi [68] Melanoma BMS936558 0.1 mg/kg
0.3 mg/kg
1.0 mg/kg
3 mg/kg
10 mg/kg
Every 2 weeks
95 20%
20%
29%
41%
20%
NR NR
Brahmer [96] NSCLC BMS936558 1.0 mg/kg
3 mg/kg
10 mg/kg
Every 2 weeks
75 6%
28%
19%
NR NR
Anti  PD-L1 antibody
Brahmer [70] Melanoma
NSCLC
CRPC
RCC
CRC
OC
PC
BMS936559
0.3 mg/kg
1.0 mg/kg
3 mg/kg
10 mg/kg
160
0
6%
29%
19%
At 24 weeks
42%◦
31%•
22%∞
NR
NR
Tykodi [97] Melanoma
NSCLC
OC
PC
RCC
CRC
BMS936559
0.3 mg/kg
1.0 mg/kg
3 mg/kg
10 mg/kg
Every 2 weeks
162
10% NR NR
NSCLC, non-small cell lung cancer; CPRC, castration-resistant prostate cancer; RCC, renal cell carcinoma; CRC, colorectal cancer; OC, ovarian cancer; PC,
pancreatic cancer; RC: rectal cancer.
# MART-1/gp100/NY-ESO-1 peptides with adjuvant Montanide ISA 51.
* 8 out of 17 patients: acute leukemia.
◦: Melanoma patients.
•: NSCLC.
∞: ovarian cancer.
NR: not reported.
N: number.
158 B. Merelli et al. / Critical Reviews in Oncology/Hematology 89 (2014) 140–165
Table 5
Ongoing clinical trials evaluating anti PD-L1 in cancer patients.
Monotherapy
Non-randomized
Drug Phase Trial Disease Primary outcome measures
MPDL3280A 1 NCT01375842 Solid tumors or hematologic
malignancies
- DLTs
BMS-936559 1 NCT01452334 Non-Hodgkin’s lymphoma
Hodgkin lymphoma
Multiple myeloma chronic
Myelogenous leukemia
- Safety
- Tolerability
MPDL3280A 2 NCT01846416 PD-L1-positive NSCLC - OR
BMS-936559 1 NCT00729664 Solid tumors - Safety
- MTD
- DLT
BMS-936559 1 NCT01455103 Melanoma - Immunomodulatory effects
Combination therapy
Non-randomized
- MPDL3280A
- Vemurafenib
1 NCT01656642 Melanoma - Incidence of DLTs
- Nature of DLTs
- Incidence, nature or severity
of adverse events and
laboratory abnormalities
- MPDL3280A
- Bevacizumab
1 NCT01633970 Advanced solid tumors - Safety
- DLTs/MTD
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LT, dose limiting toxicity; NSCLC, non-small cell lung cancer; OR, objec
reatment or until PD or CR. Ninety-five melanoma patients
ith Eastern Cooperative Oncology Group (ECOG) Perfor-
ance Status (PS) ≤  2 were treated with BMS-936558 at
.1 (n  = 13), 0.3 (n  = 17), 1 (n  = 28), 3 (n  = 17), or 10 mg/kg
n = 20). The majority of patients (60/95) had received
nterferon-alpha or IL-2 (prior anti-CTLA-4 excluded).
even out of 95 patients previously received B-raf inhibitor
herapy. Sixty out of 95 patients had previously received more
han 2 lines of treatment. The incidence of grade 3–4 related
dverse events (Aes) was 19% and included gastrointesti-
al (4%), endocrine (2%), and hepatobiliary disorders (1%).
here were no drug-related deaths. Clinical activity was
bserved at all dose levels, including patients with visceral
r bone metastases. Of 20 patients with objective response,
2 had object response duration ≥1 year, and 6 patients were
n study with objective response duration between 1.9 and
1.3 months. Several patients had prolonged stable disease.
Recently Hamid et al. evaluated the anti-PD-1 antibody
ambrolizumab at a dose of 10 mg/kg of body weight every
 or 3 weeks or 2 mg/kg every 3 weeks in 135 patients with
dvanced melanoma [69].
The confirmed response rate across all dose cohorts
as 38%, with the highest confirmed response rate, 52%,
bserved in the cohort that received 10 mg/kg every 2 weeks.
he response rate did not differ significantly between patients
retreated or not with ipilimumab. At a median follow-up of
1 months, among patients achieving a response to treat-
ent, long term responses were reported in 81% of patients.
9
t
iponse; MTD, maximum tolerated dose.
he overall median progression-free survival among the 135
atients was longer than 7 months. Common adverse events
reatment-related were fatigue, rash, pruritus, and diarrhea;
ost of the adverse events were low grade.
Finally, Brahmer et al. evaluated 207 patients (75 with
on-small cell lung cancer, 55 with melanoma, 18 with
olorectal cancer, 7 with gastric cancer, and 4 with breast
ancer), using anti-PD-L1 antibody (BMS-936559) in a mul-
icenter Phase I trial at multiple escalating dose (from 0.3
o 10 mg/kg) [70]. Anti-PD-L1 antibody was administered
very 14 days in 6-week cycles, for up to 16 cycles or until
he patient had a complete response or confirmed disease pro-
ression. Grades 3–4 immune-related toxic effects occurred
n 9% of patients. An objective response, complete or partial,
as observed in 9/52 patients with melanoma (29% response
ates at 3 mg/kg), 2/17 with renal cell cancer, 5/49 with non-
mall cell lung cancer (mostly non-squamous subgroup) and
/17 with ovarian cancer. Prolonged stabilization of disease
as observed for 12–41% lasting at 24 weeks [70].
Overall, with anti PD-1 or anti PD-L1 antibodies, the inci-
ence of serious (grade 3–4) adverse effects was at a range
imilar to that with CTLA-4-blocking antibodies, but most
ere less clinically significant with the exception of pneu-
onitis, which led to death as a result of toxicity. Blocking
he ligand PD-L1 with the fully human IgG4 antibody BMS-
36559 resulted in a slightly lower frequency of objective
umor responses and also fewer adverse effects in phase I test-
ng. These initial experiences, together with the current initial
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Table 6
Ongoing clinical trials with anti-pd-1 antibodies.
Monotherapy
Non-randomized
Drug Phase Trial Disease Primary outcome measures
BMS-936558 1 NCT01621490 Melanoma - Immunomodulatory effects
BMS-936558 1 NCT01592370 - Non-Hodgkin’s lymphoma
- Hodgkin lymphoma
- Multiple myeloma
- CML
- Safety and
- Tolerability
BMS-936558 2 NCT01721759 NSCLC - OR
BMS-936558 1 NCT01658878 HCC - Safety
BMS-936558 1 NCT00836888 Solid tumors - Safety
- Pharmacokinetic
AMP-224 1 NCT01352884 Solid tumors - Safety
- Pharmacokinetic
- Tolerability
Randomized
BMS-936558 0.3 mg/kg
versus
BMS-936558 2 mg/kg
versus
BMS-936558 10 mg/kg
(pretreated patients)
versus
BMS-936558 10 mg/kg
(naïve patients)
1 NCT01358721 RCC - Immunomodulatory activity
BMS-936558
versus
Dacarbazine
3 NCT01721772 Melanoma - OS
MK-3475
at different dose levels:
Low (0.1 mg/kg)
Intermediate (3 mg/kg)
High (10 mg/kg)
Patients with Melanoma and
NSCLC will be randomized to:
Low dose
versus
Intermediate dose
versus
High dose
1 NCT01295827 Any type of carcinoma or
Melanoma or NSCLC
Melanoma and NSCLC
- Safety
- OR
- Change from baseline in
candidate biomarker expression
levels in melanoma and NSCLC
participants
- MK-3475
versus
- Carboplatin or
- Carboplatin +
- Paclitaxel
- Paclitaxel or
- Dacarbazine or
- Temozolomide
2 NCT01704287 Melanoma - OR
- PFS
- OS
- BMS-936558
versus
- Docetaxel
3 NCT01673867 NSCLC - OS
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Table 6 (Continued)
Monotherapy
Non-randomized
Drug Phase Trial Disease Primary outcome measures
- BMS-936558
versus
- Docetaxel
3 NCT01642004 Squamous cell NSCLC - OR
- OS
- BMS-936558
versus
- Dacarbazine or
- Carboplatin or
- Paclitaxel
3 NCT01721746 Melanoma - OR
- OS
- BMS-936558
versus
- Dacarbazine
3 NCT01721772 Melanoma - OS
- BMS-936558
versus
- Everolimus
3 NCT01668784 RCC - OS
Combination therapy
Non-randomized
- BMS-936558
- NY-ESO-1
(peptide vaccine)
- gp100: 280–288
(peptide vaccine)
1 NCT01176474 Melanoma - Time to relapse in patients with
resected Stage IIIC/IV melanoma
- BMS-936558
- MART-1
(peptide vaccine)
- NY-ESO-1
(peptide vaccine)
- gp100: 209–217(210 M)
(peptide vaccine)
- gp100: 280–288(288V)
(peptide vaccine)
1 NCT01176461 Melanoma - OR
- BMS-936558
- BMS-986015
(ANTI-KIR):
1 NCT01714739 -NSCLC
-Melanoma, -RCC
-Colorectal cancer
-Ovarian cancer
- Safety and
- Tolerability
- BMS-936558
- Gemcitabine
2 NCT01313416 Pancreatic cancer - Feasibility and
- Safety
- BMS-982470
(Recombinant Interleukin-21,
rIL-21)
- BMS-936558
1 NCT01629758 Any type of carcinoma - Safety
- BMS-936558
±
- DC RCC vaccine
2 NCT01441765 RCC - Safety
- OR
- BMS-936558
±
- DC AML vaccine
2 NCT01096602 AML - Toxicity
- BMS-936558
- DC fusion vaccine
2 NCT01096602 Multiple myeloma - Immunological response
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Table 6 (Continued)
Monotherapy
Non-randomized
Drug Phase Trial Disease Primary outcome measures
- BMS-936558
- BMS-986015
(ANTI-KIR)
1 NCT01714739 Solid Tumors - Safety
- Tolerability
Randomized
- Sipuleucel-T
(vaccine)
versus
- Sipuleucel-T +
- BMS-936558
versus
- Cyclophosphamide +
- Sipuleucel-T +
BMS-936558
2 NCT01420965 Prostate cancer - Feasibility
- Immune efficacy
- BMS-936558 or
- BMS-936558 Plus – Ipilimumab
versus
Ipilimumab alone
3 NCT01844505 Melanoma - OS
NSCLC, non-small cell lung cancer; HCC, hepatocellular carcinoma; RCC, renal cell carcinoma; CML, chronic myelogenous leukemia; AML, acute myel-
ogenous leukemia; DC, dendritic cell; KIR, killer-cell immunoglobulin-like receptor; RR, response rate; PFS, progression free survival; OS, overall survival;
OR, overall response.
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tlinical testing of a series of other antibodies and blocking
onstructs to the PD-1/PD-L1 axis, provide an impetus for the
ontinued clinical testing of these highly active immunother-
pies for melanoma.
Tables 5 and 6 summarize ongoing clinical trials with anti
D-1 or anti PD-L1 antibodies.
Based on experimental data, blockade of B7-H1 or PD-1
s not expected to stimulate de novo immune responses but
ather to enhance ongoing immune responses against tumor
ntigens, since this axis is implicated in the effective phase
nd not in the priming phase of the immune response. A
ombinational strategy to elicit the immune response could
mprove the objective response rate as well as the duration of
esponse. In patients with advanced disease it is likely that
he majority of TILs have an “exhausted” phenotype. The
resence of inhibitory molecules would render these cells
nsensitive to the action of anti-PD-1. On the basis of these
onsiderations, preliminary results in mice models suggest
hat combination therapies may be helpful in restoring an
ctivating phenotype in the tumor microenvironment [71]. In
xperimental models combining B7-H1/PD-1 blockade with
ancer vaccines [72–75], adoptive transfer of preactivated T
ells, or T cell stimulation with anti-CD137 [76] often pro-
ides dramatic synergistic antitumor effects, in some cases
radicating well-established tumors.
Furthermore there is preclinical evidence that CTLA-4
nd PD-1 could play complementary roles in regulating
o
s
ndaptive immunity. Curran et al. reported, in mice xenograft,
hat the combination of CTLA-4 and PD-1 blockade deter-
ines the accumulation of CTLA-4/PD-1 double-positive
 effector cells within B16 melanoma cell lines [77]. These
ata suggest that T cells that would otherwise be functionally
nd proliferatively repressed are instead able to continue
xpanding and carrying out effector functions.
In the same model the combination of CTLA-4 and PD-1
lockade resulted more than twice as effective as either alone
n promoting the rejection of B16 melanoma cell lines. Inter-
stingly the further addition of PD-L1 antibody elevates the
ate of tumor-free survival to 65% versus 10% with CTLA-4
lockade alone [77].
Recently, on the basis of these observations, a phase 1
tudy to investigate the safety and efficacy of combined
TLA-4 and PD-1 blockade [with the use of ipilimumab
anti-CTLA4 antibody) and nivolumab (anti-PD-1 antibody),
espectively] in patients with advanced melanoma has been
onducted [78]. In this study the objective-response rate for
ll patients in the concurrent-regimen group was 40%. At the
aximum tolerated doses (nivolumab at a dose of 1 mg/kg
f body weight and ipilimumab at a dose of 3 mg/kg), 53%
f patients had an objective response, all with tumor reduc-
ion of 80% or more. Grade 3 or 4 toxicities occurred in 53%
f patients and were generally reversible and qualitatively
imilar to those reported with monotherapy (ipilimumab or
ivolumab alone).
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.  Conclusion
The past decade has seen important strides in the field of
elanoma research. Extensive research over the past twenty
ears yielded the identification of new and innovative ways to
anipulate the immune response to cancer. Negative regula-
ors of the immune system, called immunologic checkpoints,
ave been found to play important roles in restraining other-
ise effective anti-tumor immunologic responses. Therapies
hat target the PD-1/PD-L1 axis have demonstrated promis-
ng clinical results. Treatment is generally well tolerated,
ut a novel spectrum of side effects, termed immune-related
dverse events, has been experienced. Unfortunately, not
ll patients respond to these therapies, and evaluation of
iomarkers predictive of response is ongoing.
Some open issues and scarce information may unfavorably
mpact the management of patients with advanced melanoma,
herefore, priority actions are needed in this direction. In
articular:
. A standardized methodology to define the PD1/PD-L1
positive melanoma is strongly needed. Tumor heterogene-
ity in terms of PD-L1 expression, variability in the assays
and cell immunolocalization as well as cut-off values
for positive versus negative PDL-1 immunohistochemical
expression are not uniformly defined and do not currently
allow appropriate patient’s classification.
. The prognostic and predictive role of TILS (overall
estimation and/or immunophenotyping) in addition to PD-
1/PD-L1 remains to be determined in order to better
stratify patients and to identify those who may benefit
from therapies that target PD-1/PD-L1 axis.
. The anti PD-1 and PD-L1 antibodies have demonstrated
clinical activity in early clinical trials, but randomized
studies with immune correlates are lacking so far.
. Combinations of PD-L1/PD-1 blockade with cancer vac-
cines, adoptive transfer of pre-activated T cells, T cell
stimulation with anti-CD137 or MAPK inhibitors should
be investigated as they could provide synergistic antitumor
effects.
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